Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 18/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 15/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 2/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1938496 | 1.00 | HDAC3 (1.00) | HDAC3HDAC1HDAC2NCOR2HDAC8 | |
| SCHEMBL31060469 | 1.00 | HDAC3 (1.00) | HDAC3HDAC1HDAC2NCOR2HDAC8 | |
| SCHEMBL1937829 | 0.99 | HDAC3 (0.98) | HDAC3HDAC1HDAC2NCOR2HDAC8 | |
| SCHEMBL1938110 | 0.88 | HDAC3 (1.00) | HDAC3HDAC1HDAC2NCOR2HDAC8 | |
| SCHEMBL1938122 | 0.88 | HDAC3 (1.00) | HDAC3HDAC1HDAC2NCOR2HDAC8 | |
| SCHEMBL1938221 | 0.88 | HDAC3 (1.00) | HDAC3HDAC1HDAC2NCOR2HDAC8 | |
| SCHEMBL1937223 | 0.88 | HDAC3 (1.00) | HDAC3HDAC1HDAC2NCOR2HDAC8 | |
| SCHEMBL16011065 | 0.88 | HDAC4 (1.00) | HDAC3HDAC1HDAC2NCOR2HDAC8 | |
| SCHEMBL1937932 | 0.88 | HDAC3 (1.00) | HDAC3HDAC1HDAC2NCOR2HDAC8 | |
| SCHEMBL1937980 | 0.88 | HDAC1 (1.00) | HDAC3HDAC1HDAC2NCOR2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 402 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107052-A1 | COMBINATION TREATMENTS USING EPIGENETIC INHIBITION AND SYNGRI-MEDIATED FRATAXIN EXPRESSION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4720316-A2 | NON-VIRAL CELL ENGINEERING | Arsenal Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-20250268948-A1 | COMPOSITIONS AND METHODS FOR TREATING POST ACUTE SEQUELAE OF SARS-COV-2 INFECTION (LONG COVID) | AE CAPITAL LIMITED (VG) | 2025-08-28 | — | — | US | claimed |
| US-20250205286-A1 | COMPOSITIONS, REAGENTS, AND METHODS FOR TREATING PITT-HOPKINS SYNDROME | AE CAPITAL LIMITED (VG) | 2025-06-26 | — | — | US | claimed |
| US-20250188422-A1 | INDUCED TOTIPOTENT POTENTIAL STEM CELLS, METHODS OF MAKING AND USING | PEKING UNIVERSITY (CN) | 2025-06-12 | — | — | US | claimed |
| US-20250161243-A1 | MEF2 TRANSCRIPTIONAL ACTIVATORS TO TREAT NEUROLOGIC CONDITIONS | THE SCRIPPS RESEARCH INSTITUTE | 2025-05-22 | — | — | US | claimed |
| US-20250144056-A1 | ANTIMICROBIAL HOST DEFENSE PEPTIDE-INDUCING COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF | BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECH COLLEGES (US) | 2025-05-08 | — | — | US | claimed |
| US-20250115871-A1 | METHODS TO IMPROVE ENDURING HEMATOPOIETIC STEM CELL TRANSPLANTATION | TRAILHEAD BIOSYSTEMS INC. | 2025-04-10 | — | — | US | claimed |
| WO-2025059442-A1 | MODULATING PLANT RESPONSES TO STRESS AND GROWTH WITH CHEMICALS | REMOTE EPIGENETICS INC. (US) | 2025-03-20 | — | — | WO | claimed |
| US-20170231931-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-08-17 | — | — | US | claimed |
| EP-3185903-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | Fundación para la Investigación Médica Aplicada (ES) | 2017-07-05 | — | — | EP | claimed |
| CN-106604747-A | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | 基础应用医学研究基金会 | 2017-04-26 | — | — | CN | claimed |
| EP-2330894-B1 | COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS | REPLIGEN CORP (US) | 2016-12-21 | — | — | EP | claimed |
| US-20160122290-A1 | COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS | REPLIGEN CORPORATION | 2016-05-05 | — | — | US | claimed |
| WO-2016030345-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2016-03-03 | — | — | WO | claimed |
| US-9265734-B2 | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2016-02-23 | — | — | US | claimed |
| US-20120094971-A1 | Compositions Including 6-Aminohexanoic Acid Derivatives As HDAC Inhibitors | REPLIGEN CORPORATION (US) | 2012-04-19 | — | — | US | claimed |
| EP-2330894-A1 | COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS | REPLIGEN CORPORATION (US) | 2011-06-15 | — | — | EP | claimed |
| WO-2010028192-A1 | COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS | REPLIGEN CORPORATION (US) | 2010-03-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122290-A1 | COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS | HDAC1, HDAC5, HDAC2 | HDAC3 5/4885HDAC1 1/4885HDAC2 3/4885 |
| US-20170231931-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | SNCA, PSEN2, PSEN1 | HDAC3 3869/4885HDAC1 3531/4885HDAC2 2063/4885 |
| US-20120094971-A1 | Compositions Including 6-Aminohexanoic Acid Derivatives As HDAC Inhibitors | HDAC1, HDAC5, HDAC2 | HDAC3 5/4885HDAC1 1/4885HDAC2 3/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | HDAC3 97/4885HDAC1 71/4885HDAC2 432/4885 |
| US-20250161243-A1 | MEF2 TRANSCRIPTIONAL ACTIVATORS TO TREAT NEUROLOGIC CONDITIONS | MEF2D, TEAD2, TEAD1 | HDAC3 842/4885HDAC1 186/4885HDAC2 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.